Cargando…
Rapidly Destructive Coxarthrosis as a Potential Side Effect of Crizotinib in a Patient with ROS1-Positive Lung Adenocarcinoma
A 75-year-old woman was diagnosed with c-ros oncogene 1 (ROS1)-positive lung adenocarcinoma. She was treated with crizotinib 750 mg/day for 4.5 years, with partial tumor response. However, the patient subsequently presented with right hip pain and difficulty in walking. She underwent magnetic resona...
Autores principales: | Takamori, Shinkichi, Seto, Takashi, Jinnouchi, Mikako, Oba, Taro, Yamaguchi, Masafumi, Takenoyama, Mitsuhiro |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6975501/ https://www.ncbi.nlm.nih.gov/pubmed/32021222 http://dx.doi.org/10.2147/TCRM.S229860 |
Ejemplares similares
-
Brain cavernous hemangioma mimicking radiation‐induced necrosis in a patient with non‐small cell lung cancer
por: Takamori, Shinkichi, et al.
Publicado: (2020) -
Histological conversion from adenocarcinoma to small cell carcinoma of the lung after treatment with an immune checkpoint inhibitor: a case report
por: Miura, Naoko, et al.
Publicado: (2020) -
Uncommon features of surgically resected ALK-positive cavitary lung adenocarcinoma: a case report
por: Takamori, Shinkichi, et al.
Publicado: (2017) -
Prospective observational study of nutritional/immunologic indices as predictive biomarkers for the response to anti-PD-1 drugs in non-small cell lung cancer (ICI-PREDICT study)
por: Takamori, Shinkichi, et al.
Publicado: (2021) -
The impact of immune-inflammation-nutritional parameters on the prognosis of non-small cell lung cancer patients treated with atezolizumab
por: Matsubara, Taichi, et al.
Publicado: (2020)